Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432 Academic Article uri icon

Overview

MeSH Major

  • Farnesyltranstransferase
  • Leukemia, Myeloid, Acute
  • Quinolones

abstract

  • We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (>50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1-21 or days 1-7 and 15-21, repeated every 28 days (4 treatment regimens). Responses were seen in all regimens, with overall response rate (CR + CRi + PR) highest (20%) among patients receiving tipifarnib 300 mg twice daily on days 1-21. Toxicities were acceptable. Unless predictors of response to tipifarnib are identified, further study as a single agent in this population is unwarranted.

publication date

  • March 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4247790

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2013.12.001

PubMed ID

  • 24411921

Additional Document Info

start page

  • 329

end page

  • 33

volume

  • 38

number

  • 3